Immune Checkpoint Inhibitors, PD-1, and PD-L1 Explained
Both PD-L1 and PD-1 inhibitors work by disrupting the interaction between PD-L1 and PD-1, effectively “releasing the brakes” on the immune system and allowing T cells to recognize and attack cancer cells more effectively. While they target different proteins, their overall goal is the same: to enhance the immune system’s ability to fight cancer.